

Pulmonary and Systemic Nitric Oxide Measurements During CCK-5-Induced Panic Attacks

Nathalie Lara¹, Wendy E Chrapko¹, Stephen L Archer², François Bellavance³, Irvin Mayers⁴ and Jean-Michel Le Mellédo^{*,1}

¹Department of Psychiatry, University of Alberta, Canada; ²Department of Cardiology, University of Alberta, Canada; ³Department of Quantitative Methods, École des Hautes Études Commerciales, Canada; ⁴Department of Pulmonary Medicine, University of Alberta, Canada

Nitric oxide (NO) plays a major role in cardiopulmonary regulation as illustrated by the alterations of the NO system described in cardiopulmonary illnesses. Recent studies have found an association between panic disorder and cardiovascular death and illness, as well as pulmonary diseases. Our objective was to investigate whether pulmonary or systemic NO production was altered during induced panic attacks (PAs). We used a double-blind placebo-controlled crossover design with randomization of the order of an injection of placebo and pentagastrin, a cholecystokinin-B receptor agonist that induces PAs in healthy volunteers (HVs). A total of 17 HVs experienced a PA after pentagastrin challenge. Exhaled NO and NO metabolites were measured by chemiluminescence. During pentagastrin-induced PAs, HVs displayed significant decreases in plateau concentrations of NO exhaled, which were associated with proportional increases in minute ventilation. There were no significant changes in pulmonary or systemic NO production. These results suggest that the decrease in exhaled NO concentration observed during pentagastrin-induced PAs is related to the associated hyperventilation, rather than to any change in lung NO production. This study is the first to evaluate changes in NO measurements during acute anxiety.

Neuropsychopharmacology (2003) 28, 1840–1845, advance online publication, 09 July 2003; doi:10.1038/sj.npp.1300241

Keywords: nitric oxide; panic disorder; respiratory rate; minute ventilation; cardiovascular risk; cholecystokinin

INTRODUCTION

The vascular endothelium synthesizes and releases several relaxing factors, including nitric oxide (NO). NO is synthesized from the amino acid L-arginine by a family of enzymes known as nitric oxide synthases (NOS). Three isoforms of NOS have been identified and cloned: the neuronal (nNOS) and endothelial (eNOS) constitutive isoforms and the inducible (iNOS) isoform. NO is widely accepted as an important biomediator involved in the regulation of vascular and bronchial tone (Moncada *et al*, 1991; Zapol *et al*, 1994). NO has an important role in the pathophysiologic processes leading to cardiovascular and pulmonary diseases, such as reduction in NO endothelial release in atherosclerotic vessels (Cooke and Tsao, 1994) and increased NO production in respiratory diseases such as asthma (Hamid *et al*, 1997).

Panic disorder (PD) is characterized by recurrent and unexpected periods of intense fear accompanied by symptoms of a panic attack (PA) such as tremor,

palpitations, dyspnea, dizziness, paresthesias, gastric sensations, hot flushes and/or cold chills, diaphoresis, and chest pain or discomfort (American Psychiatric Association, 1994).

In the last two decades, PD has been associated with increased cardiovascular mortality and morbidity (Coryell *et al*, 1982; Coryell, 1988; Weissman *et al*, 1990; Kawachi *et al*, 1994). Furthermore, there is a high association between pulmonary illnesses and PD, as evidenced by the increased prevalence of asthma in PD patients (Spinhoven *et al*, 1994). Respiratory alterations such as persistent respiratory irregularity and increased respiratory response to the respiratory stimulant doxapram have also been reported in PD patients (Abelson *et al*, 2001). Dysregulation of the NO system in PD patients may ultimately contribute to the increased cardiovascular risk and the respiratory dysfunction associated with PD. The exact pathophysiologic mechanism of respiratory alterations in panic remains unclear. For instance, it has been hypothesized that the dyspnea experienced by PD patients may be the result of the triggering of a 'false suffocation alarm', suggesting a central abnormality in the control of ventilation (Klein, 1993). According to this theory, dyspnea would be the key symptom in the chain of events that lead to a PA. Endogenously produced NO plays an integral role in the physiological regulation of many airway functions such as bronchodilation and regulation of airway and pulmonary

*Correspondence: Dr J-M Le Mellédo, IE7.05 Mackenzie Centre, Edmonton, AB, Canada T6G 2B7, Tel: +780 407 6578, Fax: +780 407 6672, E-mail: jean-michel.lemelledo@ualberta.ca

Received 05 September 2002; revised 02 December 2002; accepted 21 January 2003

Online publication: 23 May 2003 at <http://www.acnp.org/citations/Npp0522333/default.pdf>

blood flow (Barnes and Belvisi, 1993); we therefore hypothesized that abnormal NO production could play a role in the occurrence of respiratory symptoms featured during PAs.

Cholecystokinin (CCK) type B receptor agonists such as tetragastrin (CCK-4) and pentagastrin (CCK-5) have been widely used to investigate the neurobiological changes taking place during PAs. Intravenous bolus injections of CCK-4 and CCK-5 induce short-lived PAs in PD patients and to a lesser degree in healthy volunteers (HVs) (panic response rate 70–100% and 17–70%, respectively) (Van Megen *et al*, 1996). These PAs are reported by PD patients to be very similar to the naturally occurring PA.

The direct measurement of plasma NO concentration remains difficult *in vivo* because NO is rapidly inactivated by hemoglobin or oxidized to form several nitrogen dioxides (NO_x). Plasma NO_x concentration is used as a marker for endogenous NO production in humans (Moncada *et al*, 1991). Another valid method of measurement of endogenous NO production is to assess the NO excreted in the exhaled air, detected by a chemiluminescence assay (Gustafsson *et al*, 1991; Kharitonov *et al*, 1997; Leone *et al*, 1994; Dillon *et al*, 1996; Archer *et al*, 1998).

We tested the hypothesis that CCK-5-induced PAs in HVs will be associated with increased respiratory rate, tidal volume, and alteration of NO production in exhaled breath and plasma.

METHODS

Subjects

A total of 24 normotensive subjects, taking no medications and with no evidence of medical conditions at the time of the study, were administered the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I Disorders (SCID-I) and were deemed eligible based on the lack of Axis I psychiatric disorders. As in previous studies, we used the Panic Symptom Scale (PSS) to assess the intensity of the panic response to CCK-5 and to differentiate nonpanickers from panickers (those meeting criteria for occurrence of a PA) (Bradwejn *et al*, 1991). In all, 17 out of 24 nonsmoker subjects who received CCK-5 were defined as panickers (71%) and included in the study (13 males and four females mean age \pm SEM 24.71 \pm 1.65 years). Female subjects were tested during their early follicular phase. The research protocol was approved by the Health Research Ethics Board and all subjects provided written consent.

Study Design

A double-blind placebo-controlled crossover study was undertaken. Subjects were randomized to receive intravenous 5 s-bolus of either placebo first and 3–7 days later CCK-5 (50 μ g) (CLINALFA, L aufelfingen, Switzerland), or CCK-5 first and placebo 3–7 days later.

General Procedures

Subjects followed a nitrate/nitrite restricted diet (Wang *et al*, 1997) for 3 days before the test and fasted overnight (12 h)

(Mochizuki *et al*, 2000). At 45 min before injection, an intravenous catheter was inserted into the antecubital vein for drug infusion and blood collection. Shortly after, a face mask occluding the nose was placed on the subject. Measurements were taken breath by breath from baseline (30 s interval taken before injection) up to 3 min 40 s postinjection. Calculations of tidal volume, respiratory rate, and minute/ventilation were performed using Power-lab software (AD Instruments; Castle Hill, Australia).

NO in Exhaled Breath Measurement

[NO]_{exh} was measured as previously described (Archer, 1993), using chemiluminescence analysis (NO analyzer 280; Sievers Instruments, Boulder, CO). Ambient NO contamination was avoided by the use of NO-free air (<3 ppb of NO). To exclude nasal air, known to contain high levels of NO from nasal and paranasal origin (Archer *et al*, 1998), a nonbreathing face mask was used (Hans Rudolph Inc.; Kansas City, MO). Lung NO production (VNO) by both endothelial and epithelial cells was calculated by

$$VNO_{stp} = 0.826VE([NO]_{exh}) \quad (1)$$

where VE is the minute ventilation, 0.826 is the gases universal constant (Riley *et al*, 1997), and [NO]_{exh} is the exhaled NO concentration. To obtain NO released from the lower airways (pulmonary endothelium), we calculated the plateau seen in [NO]_{exh}, as previously described in other studies (Kharitonov *et al*, 1996, 1997; Rutgers *et al*, 1998).

Classically, the mean function (*m*) has been used to obtain the plateau (defined as the interval from 1/2 to 7/8 of the duration of the exhalation) of the exhaled concentration of NO

$$\frac{\sum_{i=1}^N X(t_i)}{N}, \quad (2)$$

where $t_1 \leq t_i \leq t_N$ and $[t_0, t_N]$ is the interval of time of the plateau, *N* is the number of observations, and $X(t_i)$ is the value of the exhaled NO concentration at time t_i .

However, variations in the respiratory pattern will not be detected by this calculation and some important information can be missed. For this reason, we used the integral function (*i*) on the plateau on each breath

$$\int_{t_0}^{t_f} f(t)dt, \quad (3)$$

where $f(t)$ is the exhaled NO concentration (ppb) at time *t* and $[t_0, t_f]$ is the interval of time of the plateau (s). Therefore, more information about the behavior of the curve can be obtained, especially when the measurements of NO are carried out breath by breath with variable expiratory flows (Figure 1).

Results obtained with both methods, [NO]_{exh} (*m*) and [NO]_{exh} (*i*) will be presented.

NO_x Measurement

NO_x were measured by chemiluminescence in small volumes of plasma (10 μ l) by converting them to NO using

a strong reducing environment: vanadium (iii) in hydrochloric acid 1 N at 90°C (Archer, 1993).

STATISTICAL ANALYSIS

Following the experimental design, a linear model for crossover design (Jones and Kenward, 1989) was used to analyze the data. The following parameters were included in the model: the main effect of time, the main effect of treatment, the main effect of visit (first vs second injection visit), the main effect of order of treatment (CCK-5 first vs CCK-5s), and the following interactions: treatment with time, visit with time, and order of treatment with time. A p -value of less than 5% was considered significant. Bonferroni's multiple comparisons analyses were also carried out, where appropriate. All statistical analyses were conducted using SAS statistical software for Windows, Release 8.02 (SAS Institute Inc., Cary, NC).

RESULTS

The PSS score after CCK-5 injection was greater than after placebo injection (PSS Score means \pm SEM of 29.65 ± 2.72 after CCK-5 injection and 1.24 ± 0.58 after placebo injection. $p < 0.001$).

A significant decrease in plateau $[\text{NO}]_{\text{exh}}$ levels, for both calculations of integral function $[\text{NO}]_{\text{exh}}$ (i) (Figure 2) and mean $[\text{NO}]_{\text{exh}}$ (m) was found after pentagastrin-induced PA, but not with placebo, as illustrated by time effect and treatment \times time effect (Table 1). Bonferroni's *post hoc* analysis showed a statistically significant decrease ($p < 0.05$) in $[\text{NO}]_{\text{exh}}$ (m) at 40 s, 1 min, and 1 min 20 s compared to




Figure 1 Differences in calculations of plateau NO exhaled.

Table 1 Summary of Statistical Results

| Variables | Time effect | Treatment effect | Treatment \times time effect |
|---|--------------------------------|----------------------------|--------------------------------|
| $[\text{NO}]_{\text{exh}}$ (i) (ppb \times s) | $F(11,165) = 2.18, p = 0.018$ | $F(1,15) = 0.04, p = 0.84$ | $F(11,160) = 2.10, p = 0.02$ |
| $[\text{NO}]_{\text{exh}}$ (m) (ppb) | $F(11,165) = 3.23, p = 0.0005$ | $F(1,15) = 0.18, p = 0.68$ | $F(11,160) = 1.93, p = 0.039$ |
| V_T (l) | $F(11,165) = 4.27, p < 0.0001$ | $F(1,15) = 0.08, p = 0.78$ | $F(11,160) = 2.27, p = 0.01$ |
| RR (Hz) | $F(11,165) = 2.67, p = 0.004$ | $F(1,15) = 2.44, p = 0.14$ | $F(11,160) = 2.63, p = 0.004$ |
| VE (l/min) | $F(11,165) = 2.91, p = 0.002$ | $F(1,15) = 0.16, p = 0.69$ | $F(11,160) = 3.69, p < 0.001$ |
| VNO (i) (nl/s/min) | $F(11,165) = 1.76, p = 0.06$ | $F(1,15) = 1.52, p = 0.24$ | $F(11,160) = 1.08, p = 0.38$ |
| VNO(m) (nl/s/min) | $F(11,165) = 1.60, p = 0.10$ | $F(1,15) = 3.92, p = 0.07$ | $F(11,160) = 1.32, p = 0.22$ |
| NO_x ($\mu\text{mol/l}$) | $F(7,77) = 1.21, p = 0.31$ | $F(1,11) = 2.58, p = 0.14$ | $F(7,77) = 0.55, p = 0.79$ |

Definition of abbreviations: $[\text{NO}]_{\text{exh}}$ (i) = NO exhaled concentration plateau integral; $[\text{NO}]_{\text{exh}}$ (m) = NO exhaled concentration plateau mean; V_T = tidal volume; VE = minute ventilation; VNO (i) = NO production for plateau integral; VNO (m) = NO production for plateau mean; NO_x = plasma NO metabolites.

baseline after CCK-5-induced PAs, and at 40 and 1 min in $[\text{NO}]_{\text{exh}}$ (i). Statistically significant treatment by time interactions were found in tidal volume (Figure 3), respiratory rate (Figure 4), and minute ventilation (Figure 2) (defined as the product of tidal volume and respiratory




Figure 2 Changes (difference from baseline) in plateau $[\text{NO}]_{\text{exh}}$ (integral) and minute ventilation (VE) post-CCK-5 induced PAs. *Significant difference from baseline after Bonferroni's analysis ($p < 0.05$).




Figure 3 Changes (difference from baseline) in tidal volume (V_T) post-CCK-5-induced PA. Bars indicate the means \pm SEM $p < 0.05$. *Significant difference from baseline after Bonferroni's *post hoc* analysis ($p < 0.05$).




Figure 4 Changes in respiratory frequency during CCK-5-induced PA. Bars indicate the means \pm SEM $p < 0.05$. *Significant difference from baseline after Bonferroni's *post hoc* analysis ($p < 0.05$).

frequency) after CCK-5-induced PAs (Table 1). Bonferroni's *post hoc* analysis showed significant increases ($p < 0.05$) compared to baseline, in minute ventilation (Figure 2) and respiratory frequency (Figure 4) at 40 s, 1 min, and 1 min 20 s after CCK-5-induced PAs, and at 40 s in tidal volume (Figure 3). However, there were no statistically significant time, treatment, and time \times treatment effects in plateau NO production (VNO) (integral function and mean) after pentagastrin-induced PAs (Table 1). No significant changes were noted in plasma NO_x after CCK-5-induced PAs (Table 1).

No order of visit effect or order of treatment effect was observed on any of the variables.

DISCUSSION

In the present study, administration of CCK-5 induced intense panic symptoms compared to placebo. This is in accordance with previous CCK-5 panic challenge investigations performed in HVs (Van Megen *et al*, 1996). Previous studies have shown that PD patients display an increased panic response to CCK-4 and CCK-5 (Bradwejn *et al*, 1995; Van Megen *et al*, 1994), suggesting that CCK plays a role in the neurobiology of PD, either through an increase in central CCK neural activity or an increase in CCK receptor sensitivity (Lydiard *et al*, 1992). However, the exact mechanism leading to the occurrence of PAs remains unclear.

In the present investigation, significant increases in tidal volume (V_T), respiratory frequency (RR), and minute ventilation (VE) were found during CCK-5-induced PAs. These findings differ from a previous research report using CCK-4 in HVs. Bradwejn *et al* (1998) showed that CCK-4-induced panic symptoms produced an increase in VE mediated by increases in V_T , but not in RR. This discrepancy regarding the increase in RR between our study and Bradwejn *et al*'s could be explained by the fact that we studied only panickers (17), whereas Bradwejn *et al* (1998) studied nonpanickers (six) and panickers (nine) together. In their discussion, Bradwejn *et al* noted that the VE in panickers appear to be greater than in nonpanickers,

but the observed difference did not reach statistical significance; however, they did not provide information on RR in panickers vs nonpanickers. Our findings of an increase in RR during CCK-5-induced PA are also supported by results of other studies that used different panic challenges and that showed an increase in V_T and RR during induced PAs (Gorman *et al*, 1988, 2001). Interestingly, Goetz *et al* (1993) have described a marginally significant increase in RR during PA induced by placebo infusion in PD patients, with a peak of the RR around the same time (30 s) as the peak in RR that we observed (40 s) (Figure 4). Another human study testing the effects of CCK-4 on airway resistance found no differences in spirometric variables after CCK-4-induced panic symptoms (Shlik *et al*, 1997). Findings from these studies and our results suggest that the CCK-induced changes in respiratory function have a central rather than peripheral mechanism.

The present study is the first to investigate the changes in measurements of NO during induced anxiety/panic in humans. We found that CCK-5-induced PA produced a significant decrease in exhaled NO levels, without affecting NO production (VNO). These findings can be explained by an increase in minute ventilation such that, with constant VNO, there is a dilutional decrease in $[\text{NO}]_{\text{exh}}$. Interestingly, these ventilatory changes and associated decreased $[\text{NO}]_{\text{exh}}$ were concomitant and occurred at the time of maximum intensity of panic symptoms.

Dilutional decreases in $[\text{NO}]_{\text{exh}}$ have also been found in other situations such as exercise. During exercise, there is a decrease in $[\text{NO}]_{\text{exh}}$ and an increase in VNO for both tidal breathing and end-tidal plateau measurements of NO (Phillips *et al*, 1996). The decrease in exhaled NO concentration may be due to large increases in airflow rates, reducing the contact time between the airway wall and the exhaled air (St. Croix *et al*, 1999). Despite the decreased $[\text{NO}]_{\text{exh}}$ concentration, the large increases in ventilation during exercise can result in increased VNO. The decrease in $[\text{NO}]_{\text{exh}}$ concentration observed during exercise can also be explained by the rapid uptake of NO by the blood, due to increased diffusion of NO. However, no changes in NO metabolites (NO_x) in plasma have been found during heavy exercise (St. Croix *et al*, 1999). In contrast, in our study, no significant changes in NO production (VNO and NO_x) were found during CCK-5-induced PAs. The phenomena observed during PA may be similar to those of exercise, except that there was no increase in NO production but a stable NO production resulting from balanced changes in VE and $[\text{NO}]_{\text{exh}}$.

Increased rates of cardiovascular/cerebrovascular morbidity (Weissman *et al*, 1990) and mortality (mortality ratio for men suffering from PD was twice that of the predicted ratio) (Coryell *et al*, 1986) have been described in PD patients. This increase in cardiovascular/cerebrovascular morbidity and mortality rates may be due to the existence of chronic cardiovascular (CV) risk in PD patients, illustrated either by elevated conventional risk factors such as smoking (Amering *et al*, 1999) or by chronic physiological states such as a sympathetic predominance as suggested by the decreased heart rate variability consistently described in PD patients (Yeragani *et al*, 1998). It appears that the increased risk for sudden cardiac death found in patients with high

levels of phobic anxiety, a common feature in PD patients, persists even after correction for conventional risk factors (Kawachi *et al*, 1994). The CV risk and particularly the increased risk for sudden cardiac death associated with PD, is therefore also likely due to the acute physiological and neurochemical disturbances occurring during a PA. For example, specific panic symptoms such as palpitations, sweating, and shaking suggest an activation of the sympathetic system that could promote the occurrence of cardiac arrhythmia. We have, indeed, shown that pretreatment with intravenous propranolol blunts the panic response to CCK-4-induced PA (Le Mellédo *et al*, 1998). The respiratory alterations that accompany a PA (such as hyperventilation) observed in our study could also contribute to the acute CV risk during PA. Indeed, hyperventilation has been described to potentially precipitate coronary spasm in the presence or absence of atherosclerosis (Mansour *et al*, 1998). From our peripheral measurements of NO in HV; however, it appears that lung NO does not play a major role in respiratory changes associated with acute PAs.

In summary, this is the first study to establish that the increased minute ventilation observed during CCK-B-agonists-induced PAs was due to increases in both tidal volume and respiratory rate. We have also shown that during CCK-5-induced PAs, there is a decrease in NO concentration in exhaled breath with no alteration of pulmonary or systemic NO production. This decrease in $[NO]_{exh}$ appears to be due to an increase in minute ventilation. However, these results need to be replicated in patients with PD who are known to display a greater panic response to CCK-B receptor agonists than HVs. Although it has been suggested that NO has an important role in the central modulation of respiration, the present results only assessed the possible connection between peripheral actions of NO (such as cardiopulmonary regulation) and respiratory symptoms displayed during PAs; therefore, we cannot make any inference regarding the role of brain NO in the pathophysiology of PAs.

ACKNOWLEDGEMENTS

We thank Janisse Khudabux RN, Tom Ryan, Ross Waite, and Kyoko Hashimoto for their collaboration in the development and execution of the study. Also, we would like to thank Gustavo Carrero MSc for mathematical assistance and advice. This research was sponsored by an operating grant of the University of Alberta Hospital Foundation to JMLM and SA as well as by a Canadian Institute of Health Research (CIHR) grant to JMLM. JMLM is an AHFMR (Alberta Heritage Foundation For Medical Research) clinical investigator. SA is an AHFMR scientist, supported by the Heart and Stroke Foundation of Alberta.

REFERENCES

- Abelson JL, Weg JG, Nesse RM, Curtis GC (2001). Persistent respiratory irregularity in patients with panic disorder. *Biol Psychiatry* **49**: 588–595.
- American Psychiatric Association (1994). *DSM-IV: Diagnostic and Statistical Manual of Mental Disorders*. American Psychiatric Press: Washington, DC.
- Amering M, Bankier B, Berger P, Griengl H, Windhaber J, Katschnig H (1999). Panic disorder and cigarette smoking behavior. *Compr Psychiatry* **140**: 35–38.
- Archer SL (1993). Measurement of nitric oxide in biological models. *FASEB J* **7**: 349–360.
- Archer SL, Djaballah K, Humbert M, Weir KE, Fartoukh M, Dall'ava-Santucci J *et al* (1998). Nitric Oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. *Am J Respir Crit Care Med* **158**: 1061–1067.
- Barnes PJ, Belvisi MG (1993). Nitric oxide and lung disease. *Thorax* **48**: 1034–1043.
- Bradwejn J, LeGrand J-M, Koszycki D, Bates JHT, Bourin M (1998). Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. *Am J psychiatry* **155**: 280–282.
- Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A (1995). Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. *Biol Psychiatry* **38**: 742–746.
- Bradwejn J, Koszycki D, Shriqui C (1991). Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder; clinical and behavioral findings. *Arch Gen Psychiatry* **48**: 603–610.
- Cooke JP, Tsao PS (1994). Is NO an endogenous antiatherogenic molecule? *Arterioscler Thromb* **14**: 653–655.
- Coryell W (1988). Panic disorder and mortality. *Psychiatr Clin North Am* **11**: 433–440.
- Coryell W, Noyes R, Clancy J (1982). Excess mortality in panic disorder. *Arch Gen Psychiatry* **39**: 701–703.
- Coryell W, Noyes R, Hause JD (1986). Mortality among outpatients with anxiety disorders. *Am J Psychiatry* **143**: 508–510.
- Dillon WC, Hampl V, Schultz PJ, Rubins JB, Archer SL (1996). Origins of breath nitric oxide in humans. *Chest* **110**: 930–938.
- Goetz RR, Klein DF, Kahn J, Liebowitz MR, Fyer AJ, Gorman JM (1993). Panic attacks during placebo procedures in the laboratory. Physiology and symptomatology. *Arch Gen Psychiatry* **50**: 280–285.
- Gorman JM, Goetz R, Martinez J, Uy J, Ross D, Fyer AJ *et al* (1988). Hyperventilation occurs during lactate-induced panic. *J Anxiety Disord* **2**: 193–202.
- Gorman JM, Kent J, Martinez J, Browne S, Coplan J, Papp LA (2001). Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression and premenstrual dysphoric syndrome. *Arch Gen Psychiatry* **58**: 125–131.
- Gustafsson LE, Leone AM, Person MG, Wiklund NP, Moncada S (1991). Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. *Biochem Biophys Res Commun* **181**: 852–857.
- Hamid Q, Springall DR, Riveros-Moreno V (1997). Induction of nitric oxide synthase in asthma. *J Allergy Clin Immunol* **100**: 624–629.
- Jones B, Kenward MG (1989). *Design and Analysis of Cross-Over Trials*. Chapman & Hall: New York.
- Kawachi I, Colditz GA, Ascherio A, Rimm EB, Giovanucci E, Stampfer MJ *et al* (1994). Prospective study of phobic anxiety and risk of coronary heart disease in men. *Circulation* **89**: 1992–1997.
- Kharitonov S, Alving K, Barnes PJ (1997). Exhaled and nasal nitric oxide measurements: recommendations. *Eur Res J* **10**: 1683–1693.
- Kharitonov S, Chung KF, Evans DJ, O'Connor BJ, Barnes PJ (1996). Increased exhaled nitric oxide in asthma is derived from the lower respiratory tract. *Am J Respir Crit Care Med* **153**: 1773–1780.
- Klein DF (1993). False suffocation alarms, spontaneous panic and related conditions: an integrative hypothesis. *Arch Gen Psychiatry* **50**: 306–317.

- Le Mellédo J-M, Bradwejn J, Koszycki D, Bichet DG, Bellavance F (1998). The role of the B-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. *Biol Psychiatry* **44**: 364–366.
- Leone AM, Gustafsson LE, Francis PL, Persson MG, Wiklund NP, Moncada S (1994). Nitric oxide in exhaled breath in humans: direct GC-MS confirmation. *Biochem Biophys Res Commun* **201**: 883–887.
- Lydiard RB, Ballenger JC, Laraie MT, Fossey MD, Beinfeld MC (1992). CSF cholecystokinin concentrations in patients with panic disorder and normal comparison subjects. *Am J Psychiatry* **149**: 691–693.
- Mansour VM, Wilkinson DJC, Jennings GL, Schwarz RG, Thompson JM, Esler MD (1998). Panic disorder: coronary spasm as a basis for cardiac risk? *Med J Aust* **168**: 390–392.
- Mochizuki S, Toyota E, Hiramatsu O, Kajita T, Shigeto F, Takemoto M et al (2000). Effect of dietary control on plasma nitrate level and estimation of basal systemic nitric oxide production rate in humans. *Heart Vessels* **15**: 274–279.
- Moncada S, Palmer RMJ, Higgs EA (1991). Nitric oxide: physiology, pathophysiology and pharmacology. *Pharmacol Rev* **43**: 109–143.
- Phillips CR, Giraud GD, Holden WE (1996). Exhaled nitric oxide during exercise: site of release and modulation by ventilation and blood flow. *J Appl Physiol* **80**: 1865–1871.
- Riley MS, Pórszász J, Miranda J, Engelen MPKJ, Brundage B, Wasserman K (1997). Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. *Chest* **111**: 44–50.
- Rutgers SR, Meijer RJ, Kerstjens HAM, van der Mark ThW, Koëter GH, Postma DS (1998). Nitric oxide measured with single-breath and tidal-breathing methods in asthma and COPD. *Eur Respir J* **12**: 816–819.
- Shlik J, Vasar V, Aluoja A, Kingisepp P-H, Jagomägi K, Vasar E et al (1997). The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. *Biol Psychiatry* **42**: 206–212.
- Spinhoven P, Ros M, Westgeest A, Van der Does AJ (1994). The prevalence of respiratory disorders in panic disorder, major depressive disorder and V-code patients. *Behav Res Ther* **32**: 647–649.
- St. Croix CM, Wetter TJ, Pegelow DF, Meyer KC, Dempsey JA (1999). Assessment of nitric oxide formation during exercise. *Am J Respir Crit Care Med* **159**: 1125–1133.
- Van Megen HJGM, Westenberg HGM, den Boer JA, Haigh JRM, Traub M (1994). Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. *Psychopharmacology* **114**: 449–455.
- Van Megen HJGM, Westenberg HGM, den Boer JA, Kahn RS (1996). Cholecystokinin in anxiety. *Eur Neuropsychopharmacol* **6**: 263–280.
- Wang J, Brown MA, Tam SH, Chan MC, Whitworth JA (1997). Effects of diet on measurement of NO metabolites. *Clin Exp Pharmacol Physiol* **24**: 418–420.
- Weissman MM, Markowitz JS, Oulette R, Greenwald S, Kahan JP (1990). Panic disorder and cardiovascular/cerebrovascular problems: results from a community survey. *Am J Psychiatry* **147**: 1504–1508.
- Yeragani VK, Sobolewski E, Igel G, Johnson C, Jampala VC, Kay J et al (1998). Decreased heart-period variability in patients with panic disorder: a study of Holter ECG records. *Psychiatry Res* **78**: 89–99.
- Zapol WM, Rimar S, Gillis N (1994). Nitric oxide and the lung. Summary of an NHLBI workshop. *Am J Respir Crit Care Med* **149**: 1375–1380.